Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Mineralys Therapeutics, Inc.: Filed amended and restated certificate of incorporation upon IPO closing, increasing authorized common stock to 500M shares, authorizing 50M undesignated preferred shares, establishing a classified board, requiring cause for director removal, and eliminating stockholder action by written consent (effective 2023-02-14).
- Change
- charter amendment
- Effective
- 2023-02-14
Exact text from the filing
On February 14, 2023, Mineralys Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Mineralys Therapeutics, Inc.: Amended and restated bylaws to establish procedures for stockholder proposals and director nominations, and conform to amended charter (effective 2023-02-14).
- Change
- bylaw amendment
- Effective
- 2023-02-14
Exact text from the filing
On February 14, 2023, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Company’s board of directors to become effective upon the effectiveness of the Restated Certificate, became effective.
View on SEC.gov